◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › ANNX

Annexon, Inc. (ANNX) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-26

Annexon, Inc. (ANNX) operates in the Biotechnology industry and is headquartered in Brisbane, United States with about 93 employees. Its market capitalization is roughly $855 million. In the fiscal year ended 2025-12-31, ANNX reported $0M in revenue and ($207M) in net income.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.

Interactive charts & full statements →

ANNX Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($216M)($154M)($144M)($146M)
Net Income($207M)($138M)($134M)($142M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANNX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($46M)($50M)($57M)($52M)($57M)
Net Income($44M)($48M)($55M)($49M)($54M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANNX Free Cash Flow History

ANNX Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$278M$350M$298M$285M
Total Liabilities$66M$57M$47M$54M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ANNX viewer.

Other Companies in Biotechnology

← ANNAAll stocksANPA →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.